Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1 4Phase 4 2Phase 3 1Phase 1/2 1

Status

Recruiting 2Terminated 1Completed 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 4

Conditions

Neoplasms 1520Carcinoma, Non-Small-Cell Lung 754Breast Neoplasms 572Neoplasm Metastasis 529Colorectal Neoplasms 445Melanoma 391Leukemia, Myeloid, Acute 371Multiple Myeloma 363Ovarian Neoplasms 352Recurrence 336Lymphoma 334Advanced Solid Tumors 324Lymphoma, Non-Hodgkin 314Prostatic Neoplasms 300Pancreatic Neoplasms 285Advanced Solid Tumor 240Stomach Neoplasms 232Carcinoma, Renal Cell 225Squamous Cell Carcinoma of Head and Neck 210Lung Neoplasms 210Solid Tumor 204Leukemia, Lymphocytic, Chronic, B-Cell 198Triple Negative Breast Neoplasms 183Solid Tumors 182Carcinoma, Hepatocellular 164Hematologic Neoplasms 155Head and Neck Neoplasms 152Lymphoma, Large B-Cell, Diffuse 148Lymphoma, Follicular 146Glioblastoma 145

Interventions

relugolix 1apalutamide 1abiraterone 1Prednisone 1Methylprednisolone 1Lutetium-177 1Lutetium 1Gonadotropin-Releasing Hormone 1Docetaxel 1Abiraterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1 × INDUSTRY × Metastatic Castration-Resistant Prostate Cancer × Clear all
NCT06318273 2026-04-08

A Study to Assess Adverse Events, and How Intravenously (IV) Infused ABBV-969 Moves Through the Bodies of Adult Participants With Metastatic Castration-Resistant Prostate Cancer

AbbVie

Phase 1 Recruiting
230 enrolled
Genitourinary

Metastatic Castration-Resistant Prostate Cancer

NCT06531499 2025-12-31

RADIODOSE

Novartis

Phase 1 Recruiting
106 enrolled
Genitourinary

Metastatic Castration-Resistant Prostate Cancer

NCT04666129 2025-08-17

Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer

Sumitomo Pharma America, Inc.

Phase 1 Completed
48 enrolled
Genitourinary

Metastatic Castration-Resistant Prostate Cancer

NCT03137758 2020-03-09

A Phase I Study of PCUR-101 in Combination With Androgen Suppression Therapy in the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer

Pellficure Pharmaceuticals, Inc

Phase 1 Terminated
12 enrolled
Genitourinary

Metastatic Castration-Resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡